Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GenovaTSE:9341 -0.97%77 EBITDA Margin % is 9.44% as of Mar. 2026, which is 58% below its 10-year median of 22.35. GuruFocus rates TSE:9341 with a GF Score™ of 77/100 and a GF Value™ of 円1,961.82 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Genova ranks worse than 53.19% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Genova's EBITDA for the
six
months ended in Mar. 2026 was 円622 Mil. Genova's Revenue for the
six
months ended in Mar. 2026 was 円6,591 Mil. Therefore, Genova's EBITDA margin for the quarter that ended in Mar. 2026 was 9.44%.
Genova (TSE:9341) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Genova EBITDA Margin % Related Terms
Genova EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Genova's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:9341 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Genova's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genova EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Genova's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Genova's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genova (TSE:9341) has a EBITDA Margin % of 9.44% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Genova and its competitors. This is 58% below median its historical median of 22.35. Over the past decade, Genova's EBITDA Margin % has ranged from 5.68 to 27.82. According to the industry distribution chart, Genova ranks #434 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 53.2%.
Is Genova's EBITDA Margin % too high?
Genova's current EBITDA Margin % of 9.44% is 58% below median its 10-year median of 22.35. Over the past 10 years, this metric has ranged from a low of 5.68 to a high of 27.82. The Medical Devices & Instruments industry median EBITDA Margin % is 7.46. Genova's value of 9.44% is 26.6% above this industry median. Based on the distribution chart, Genova ranks #434 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Genova has a GF Score™ of 77/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Genova's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Genova ranks #434 out of 816 companies for EBITDA Margin %. This places Genova in the lower half of its industry. The industry median EBITDA Margin % is 7.46. Genova's value of 9.44% is 26.6% above this benchmark. Historically, Genova's own EBITDA Margin % has ranged from 5.68 to 27.82 over the past decade. While the company's 10-year median is 22.35 vs. the industry median of 7.46, Genova has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.46, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genova's current EBITDA Margin % of 9.44% is 26.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Genova and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genova's current EBITDA Margin % is 9.44%, which is 58% below median its own 10-year median of 22.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genova stock overvalued right now?
Based on GuruFocus' analysis, Genova (TSE:9341) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,961.82, compared to a current price of 円611.00 — trading 68.9% below its estimated fair value. The current EBITDA Margin % is 9.44%, which is 58% below median its 10-year median of 22.35 and 26.6% above the Medical Devices & Instruments industry median of 7.46. Genova's overall GF Score™ is 77/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Genova (TSE:9341), the current EBITDA Margin % is 9.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genova (TSE:9341) Overvalued in 2026?
Based on GuruFocus' analysis, Genova stock appears to be undervalued.
The current stock price of 円611.00 is trading 68.9% below its estimated GF Value™ of 円1,961.82.
GuruFocus considers Genova to be Possible Value Trap.
Key valuation signals for TSE:9341:
EBITDA Margin %: 9.44% (58% below median its 10-year median of 22.35)
GF Value™: 円1,961.82 vs. price of 円611.00 (68.9% below fair value)
Industry Position: 26.6% above the Medical Devices & Instruments median (#434 of 816)
No single metric tells the full story. See the TSE:9341 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genova Inc manages operations of the medical information site and sales of automatic reception and payment machines for clinics. The group operates in two reportable segments: Medical Platform Business and the Smart Clinic Project. The majority of its revenue is generated from the Medical Platform Business, which operates an online media site (Medical Dock) that provides preventive information and health knowledge to users (patients) on diseases and symptoms. In addition, it also supports users in finding a family doctor that suits them. The Smart Clinic Business develops and provides services that improve the convenience and efficiency of non-medical procedures at medical institutions.
77GF Score
Get the complete analysis for TSE:9341
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:9341 has been successfully added to your 
